Current regulatory approaches for accessing potential COVID-19 therapies

Vesa Halimi1 Faculty of Pharmacy, University Ss. Cyril and Methodius,Skopje,North Macedonia.

Armond Daci2 Department of Pharmacy, Faculty of Medicine,University of Prishtina,Prishtina,Kosovo.

Simona Stojanovska3 University Clinic of Hematology, Medical Faculty, University Ss. Cyril and Methodius,Skopje,North Macedonia.

Irina Panovska-Stavridis3 University Clinic of Hematology, Medical Faculty, University Ss. Cyril and Methodius,Skopje,North Macedonia.

Milena Stevanovic4 University Clinic of Infection diseases and febrile conditions, Medical Faculty, University Ss. Cyril and Methodius,Skopje,North Macedonia.

Venko Filipce5 University Clinic for Neurosurgery, Medical Faculty, University Ss. Cyril and Methodius,Skopje,North Macedonia.

Aleksandra Grozdanova1 Faculty of Pharmacy, University Ss. Cyril and Methodius,Skopje,North Macedonia.Correspondence[email protected]

https://orcid.org/0000-0002-0098-8691

show all

Current regulatory approaches for accessing potential COVID-19 therapies

Table 1 Regulatory attributes of clinical trials, compassionate use, emergency use and off-label use

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Current regulatory approaches for accessing potential COVID-19 therapies

Figures & data

Table 1 Regulatory attributes of clinical trials, compassionate use, emergency use and off-label use

Availability of data and materials

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date